- Chinese National Medical Products Administration (NMPA) approved Gilenya® for relapsing forms of multiple sclerosis (RMS) for adults and children 10 years and older.
- Multiple sclerosis (MS) is categorized as rare disease in China with an estimated 30,000 MS patients in China.
- Gilenya is the 3rd most prescribed MS disease modifying treatment worldwide. Today, Gilenya is widely recognized by doctors with over 283,000 patients treated with Gilenya to date[1].
- Novartis is committed to bringing innovation to China and to reimagining care for patients. Entresto® was approved in 2017. Following the approval of Cosentyx® in March, Gilenya is the next key Novartis product approved from the list of urgently needed drugs in China.
Friday, July 19, 2019
Novartis key multiple sclerosis product Gilenya approved in China
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.